GENE EDITING 101
All Companies
🇯🇵

Modalis Therapeutics

Public

Epigenome editing from Japan

Modalis Therapeutics is a Japanese clinical-stage company developing epigenome editing therapies using its proprietary CRISPR-GNDM (Guide Nucleotide-Directed Modulation) platform. The company focuses on neurological disorders and has a collaboration with JCR Pharmaceuticals for CNS gene therapy.

Founded2016
HQTokyo, Japan
CEOKenichiro Arai
TickerTSE:4883
Total Funding$120M

Pipeline

Drug / ProgramIndicationPhaseTechnology
MDL-101Muscular DystrophyPreclinicalCRISPR-GNDM
JCR/Modalis CNS programCNS DisordersPreclinicalEpigenome Editing

Key People

Kenichiro AraiCEO

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read